Open Payments

The Stamford Hospital

Type
Teaching hospital
Where
Stamford, CT
Medicare CCN
070006
Received
$424,199 in 55 records, 2023 ($52,368 general, $371,830 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2023General payment20$52,368
2023Research payment35$371,830

By company

CompanyRecordsAmountYears
PFIZER INC.13$286,0322023
Sumitomo Pharma America, Inc.8$43,3912023
AstraZeneca Pharmaceuticals LP4$28,7142023
Stryker Corporation4$16,8402023
Genentech, Inc.3$16,0182023
Celgene Corporation2$13,7052023
E.R. Squibb & Sons, L.L.C.1$4,2052023
Tandem Diabetes Care, Inc.8$3,2002023
LEICA MICROSYSTEMS INC.1$2,9492023
Incyte Corporation2$2,6822023
EMD Serono, Inc.2$1,8032023
SEAGEN INC.1$1,5332023
Eli Lilly and Company1$1,2822023
CSL Behring1$5002023
Haemonetics Corporation1$5002023
ABBVIE INC.1$4632023
CONMED Corporation1$3292023
ZOLL Medical Corporation1$502023

By nature of payment

NatureRecordsAmount
Research payment35$371,830
Charitable Contribution1$25,000
Debt forgiveness4$13,653
Long term medical supply or device loan3$6,515
Space rental or facility fees (teaching hospital only)3$3,500
Compensation for services other than consulting, including serving as faculty or as a speaker at a v8$3,200
Education1$500

Records

DateCompanyAmountNatureFormProductStudyYear
2023-12-31Stryker Corporation$12,765Debt forgivenessCash or cash equivalent2023
2023-12-31Stryker Corporation$3,516Long term medical supply or device loanIn-kind items and servicesREMB Device, SURGICAL2023
2023-12-31Stryker Corporation$475Debt forgivenessCash or cash equivalent2023
2023-12-31ABBVIE INC.$463Research paymentIn-kind items and servicesA Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Part2023
2023-12-31Stryker Corporation$83Debt forgivenessCash or cash equivalent2023
2023-12-30PFIZER INC.$21,221Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2023
2023-12-27Haemonetics Corporation$500EducationCash or cash equivalent2023
2023-12-21Incyte Corporation$1,341Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo2023
2023-12-20EMD Serono, Inc.$675Research paymentCash or cash equivalentBAVENCIO Drug, OncologyPATRIOT II US Prospective 1st Line Maintenance of Avelumab in UC-20202023
2023-12-20Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2023
2023-12-15PFIZER INC.$34,257Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2023
2023-12-08PFIZER INC.$24,397Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2023
2023-12-04AstraZeneca Pharmaceuticals LP$25,000Charitable ContributionCash or cash equivalent2023
2023-11-29Incyte Corporation$1,341Research paymentCash or cash equivalentA Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants2023
2023-11-10PFIZER INC.$7,580Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2023
2023-11-01Sumitomo Pharma America, Inc.$3,562Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2023
2023-11-01Sumitomo Pharma America, Inc.$2,864Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2023
2023-11-01Sumitomo Pharma America, Inc.$821Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2023
2023-11-01Sumitomo Pharma America, Inc.$410Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2023
2023-10-17PFIZER INC.$11,370Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2023
2023-10-03PFIZER INC.$7,541Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2023
2023-09-20Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2023
2023-09-14LEICA MICROSYSTEMS INC.$2,949Long term medical supply or device loanIn-kind items and servicesSENTIMAG Device, Devices2023
2023-09-01Genentech, Inc.$11,602Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2023
2023-08-30Sumitomo Pharma America, Inc.$11,226Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2023
2023-07-27PFIZER INC.$2,461Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2023
2023-07-25Genentech, Inc.$2,510Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2023
2023-07-14ZOLL Medical Corporation$50Long term medical supply or device loanIn-kind items and services Device, DEFIBRILLATOR2023
2023-07-08PFIZER INC.$57,507Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2023
2023-07-07EMD Serono, Inc.$1,128Research paymentCash or cash equivalentBAVENCIO Drug, OncologyPATRIOT II US Prospective 1st Line Maintenance of Avelumab in UC-20202023
2023-06-19CSL Behring$500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2023
2023-06-07Tandem Diabetes Care, Inc.$600Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2023
2023-05-31PFIZER INC.$37,070Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2023
2023-05-22CONMED Corporation$329Debt forgivenessIn-kind items and services2023
2023-05-18Tandem Diabetes Care, Inc.$600Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2023
2023-05-12PFIZER INC.$37,108Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2023
2023-05-11E.R. Squibb & Sons, L.L.C.$4,205Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase III Study - Breast Cancer HR Pos / HER2 Neg Neo adjuvant2023
2023-04-25SEAGEN INC.$1,533Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2023
2023-04-24AstraZeneca Pharmaceuticals LP$1,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentIMFINZI Biological, Oncology2023
2023-04-19Sumitomo Pharma America, Inc.$8,894Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2023
2023-04-18AstraZeneca Pharmaceuticals LP$714Research paymentCash or cash equivalentIMFINZI Biological, OncologyA Non-Interventional Primary Data Collection Study to Assess the Prevalence of PD-L1 High in First Line Metastatic and L2023
2023-04-03Genentech, Inc.$1,906Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2023
2023-03-31PFIZER INC.$11,289Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2023
2023-03-24Celgene Corporation$7,205Research paymentCash or cash equivalentConnect MM- The Multiple Myeloma Disease Registry2023
2023-03-17AstraZeneca Pharmaceuticals LP$1,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentENHERTU Biological, Oncology2023
2023-03-15Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2023
2023-03-08Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2023
2023-02-23Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2023
2023-02-15PFIZER INC.$19,146Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2023
2023-02-08Eli Lilly and Company$1,282Research paymentIn-kind items and servicesA PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VE2023
2023-01-26Sumitomo Pharma America, Inc.$10,612Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2023
2023-01-26Sumitomo Pharma America, Inc.$5,000Research paymentCash or cash equivalentORGOVYX Drug, HORMONE THERAPYA MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX2023
2023-01-25Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2023
2023-01-18Celgene Corporation$6,500Research paymentCash or cash equivalentRevlimid Drug, HematologyConnect MDS/AML - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (A2023
2023-01-07PFIZER INC.$15,079Research paymentCash or cash equivalentA PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM2023

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Western Connecticut Planning RegionStamford city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Stamford, CT, county Western Connecticut Planning Region, CT, state Connecticut; placed by its city name.

MeasurePlace (city or town)
Stamford, CT
County
Western Connecticut Planning Region, CT
State
Connecticut
Population B01003137,144627,0713,624,508
Population, 2020 census P1135,470-3,605,944
Median age B0100238.441.541.1
Under 18 B0100118.4%21.8%20.2%
65 and over B0100116.2%17.4%18.5%
Households B1100155,291235,3791,434,007
Foreign born B0500231.3%23.8%15.7%
Median household income B19013$111,586$128,188$95,781
Median family income B19113$126,493$161,625$122,706
Per capita income B19301$67,068$82,266$55,915
Poverty rate B1700110.1%7.5%10.0%
Unemployment rate B230254.9%5.3%5.6%
Civilian labor force B2302581,944346,5571,959,490
Mean commute (minutes) B0801328.530.826.5
Bachelor's degree or higher B1500351.7%55.5%42.5%
Housing units B2500158,655251,5301,541,822
Owner-occupied B2500348.8%66.4%66.5%
Renters B2500351.2%33.6%33.5%
Median home value B25077$624,400$652,900$366,900
Median gross rent B25064$2,276$2,110$1,488
White, not Hispanic B0300243.2%58.6%61.9%
Black B0300217.7%9.3%9.8%
Hispanic or Latino B0300228.3%20.5%18.3%
Asian B030027.3%5.4%4.7%
American Indian and Alaska Native B030020.1%0.1%0.1%

Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); Unemployment rate: 4.7% in Sep 2016 to 5.1% in Sep 2026; low 3.1%, high 11.9% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Stamford, CT.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.